ANALYSIS OF THE FEATURES OF THE COURSE OF COVID-19 IN PATIENTS WITH METABOLIC DISORDERS
DOI:
https://doi.org/10.11603/1681-2786.2023.1.13539Keywords:
coronavirus disease, diabetes, population protection, predictor, risk factorAbstract
Purpose: to identify prognostic criteria for the severe course of COVID-19 in patients with metabolic disorders depending on body mass index, age and existing comorbid pathology, clinical and laboratory data.
Materials and Methods. Research methods: systemic approach, medical-statistical, structural-logical analysis, clinical methods, laboratory, instrumental.
Results. A high frequency of metabolic pathology, in particular the frequency of diabetes and hyperglycemia in patients with a severe course of the coronavirus disease, was revealed, which requires risk correction at both the individual and population levels. Excess adipose tissue in the human body is a modifiable factor, unlike age and gender.
Conclusions. 1. Providing medical care in conditions of mass sanitary losses during the pandemic required ranking patients according to individual risk. The search for means of assessing predictors of the severe course of the coronavirus disease continues.
2. In the case of coronavirus disease, the mechanism of influence is determined both by the direct effect of the virus on target organs and indirectly through immune inflammation. The level of background chronic inflammation before the onset of the coronavirus disease in patients with metabolic disorders with excess adipose tissue is an independent risk factor and requires timely appointment of therapy, as well as assessment of risk groups requiring hospitalization.
3. The tactics of treating patients depends on the initial assessment of anthropometric data, initial clinical and laboratory data, and existing accompanying pathology.
References
Babinets, L.S. (Ed.). (2021). Koronavirusna khvoroba: pidkhody do vedennya patsiyentiv [Corona virus disease: approaches to patient management]. Ternopil: Osadtsa Yu.V. [in Ukrainian].
Tronko, M.D. (2019). Vyklyky ta realiyi suchasnoyi endokrynolohichnoyi sluzhby: fudamentalna ta prykladna nauka v klinichniy endokrynolohiyi [Challenges and realities of modern endocrinology service: fundamental and applied science in clinical endocrinology]. Zdorovya Ukrayiny – Health of Ukraine, 49-52. Retrieved from: http://health-ua.com/multimedia/4/1/8/5/1/1556278950.pdf [in Ukrainian].
Antonyuk, O., Shatylo, S., & Kuchynska, I. (2021). COVID-19 in diabetic and non-diabetic patients hospitalized to private medical center: a retrospective analysis Presented at Society for Endocrinology BES 2021, Harrogate, UK. Endocrine Abstracts. Retrieved from: https://www.endocrine-abstracts.org/ea/0073/ea0073ep120. DOI: https://doi.org/10.1530/endoabs.73.EP120
Liu, Z., Li, J., Huang, J., Guo, L., Gao, R., Luo, K., … Wu, X. (2020). Association Between Diabetes and COVID-19: A Retrospective Observational Study With a Large Sample of 1,880 Cases in Leishenshan Hospital, Wuhan. Frontiers in Endocrinology, 11, 478. DOI 10.3389/fendo.2020.00478. DOI: https://doi.org/10.3389/fendo.2020.00478
Cinti, F., & Cinti, S. (2022). The Endocrine Adipose Organ: A System Playing a Central Role in COVID-19. Cells, 11(13).DOI 10.3390/cells11132109. DOI: https://doi.org/10.3390/cells11132109
Ng, W.H., Tipih, T., Makoah, N.A., Vermeulen, J.G., Goedhals, D., Sempa, J.B., … Mahalingam, S. (2021). Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis. mBio, 12(1).DOI 10.1128/mBio.03647-20. DOI: https://doi.org/10.1128/mBio.03647-20
Steenblock, C., Schwarz, P.E.H., Ludwig, B., Linkermann, A., Zimmet, P., Kulebyakin, K., … Bornstein, S.R. (2021). COVID-19 and metabolic disease: mechanisms and clinical management. The Lancet Diabetes & Endocrinology, 9(11), 786-798. DOI 10.1016/S2213-8587(21)00244-8. DOI: https://doi.org/10.1016/S2213-8587(21)00244-8
(2021). COVID-19 coronavirus pandemic. www.worldometers.info. Retrieved from: https://www.worldometers.info/coronavirus/.
Halushko, O.A., Trishchynska, M.A., Povietkina, T.M., & Boliuk, M.V. (2020). Diabetes mellitus in COVID-19 patients: verdict or not? Wiadomosci Lekarskie (Warsaw, Poland, 1960), 73(12, 1), 2672-2676. DOI: https://doi.org/10.36740/WLek202012121
Farag, Y.M., & Gaballa, M.R. (2011). Diabesity: an overview of a rising epidemic. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association, 26(1), 28-35. DOI 10.1093/ndt/gfq576. DOI: https://doi.org/10.1093/ndt/gfq576
Guarisco, G., & Leonetti, F. (2021). COVID-19 and diabesity: when a pandemia cross another pandemia. Eating and weight disorders: EWD, 26(5), 1283-1286. DOI 10.1007/s40519-020-00958-9. DOI: https://doi.org/10.1007/s40519-020-00958-9
Huang, I., Lim, M.A., & Pranata, R. (2020). Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – a systematic review, meta-analysis, and meta-regression. Diabetes Metab. Syndr., 14, 395-403. DOI: https://doi.org/10.1016/j.dsx.2020.04.018
Saito, T., Yamaguchi, T., Kuroda, S., Kitai, T., Yonetsu, T., Kohsaka, S., … Kodama, T. (2022). Impact of body mass index on the outcome of Japanese patients with cardiovascular diseases and/or risk factors hospitalized with COVID-19 infection. Journal of Cardiology, 79(4), 476-481. DOI 10.1016/j.jjcc.2021.09.013. DOI: https://doi.org/10.1016/j.jjcc.2021.09.013
Mankovsky, B., & Halushko, O. (2020). COVID-19 in diabetes patients in Ukraine: lessons for doctors and patients. Georgian medical news, 301, 105-112.
Morys, F., & Dagher, A. (2021). Poor Metabolic Health Increases COVID-19-Related Mortality in the UK Biobank Sample. Frontiers in Endocrinology, 12. DOI 10.3389/fendo.2021.652765. DOI: https://doi.org/10.3389/fendo.2021.652765
Nguyen, D.M., & El-Serag, H.B. (2010). The epidemiology of obesity. Gastroenterology Clinics of North America, 39(1), 1-7. DOI 10.1016/j.gtc.2009.12.014. DOI: https://doi.org/10.1016/j.gtc.2009.12.014
Wittermans, E., Grutters, J.C., Moeniralam, H.S., Ocak, G., Voom, G.P., Bos, W.J.W., & van de Garde, E.M.V. (2022). Overweight and obesity are not associated with worse clinical outcomes in COVID-19 patients treated with fixed-dose 6 mg dexamethasone. Int. J. Obes., 46, 2000-2005. DOI 10.1038/s41366-022-01204-1. DOI: https://doi.org/10.1038/s41366-022-01204-1
Richardson, S., Hirsch, J.S., Narasimhan, M., Crawford, J.M., McGinn, T., Davidson, K.W., … Zanos, T.P. (2020). Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA, 323(20), 2052-2059. DOI 10.1001/jama.2020.6775. DOI: https://doi.org/10.1001/jama.2020.6775
Kang, M.K., Lee, Y.R., Song, J.E., Kweon, Y.O., Tak, W.Y., Jang, S.Y., … Park, S.Y. (2022). Prognostic Impact of Myosteatosis on Mortality in Hospitalized Patients with COVID-19. Diagnostics (Basel, Switzerland), 12(9). DOI 10.3390/diagnostics12092255. DOI: https://doi.org/10.3390/diagnostics12092255
Lim, S., Shin, S.M., Nam, G.E., Jung, C.H., & Koo, B.K. (2020). Proper Management of People with Obesity during the COVID-19 Pandemic. Journal of Obesity & Metabolic Syndrome, 29(2), 84-98. DOI 10.7570/jomes20056. DOI: https://doi.org/10.7570/jomes20056
Khalangot, M., Sheichenko, N., Gurianov, V., Vlasenko, V., Kurinna, Y., Samson, O., & Tronko, M. (2022). Relationship between hyperglycemia, waist circumference, and the course of COVID-19: Mortality risk assessment. Experimental Biology and Medicine (Maywood, N.J.), 247(3), 200-206. DOI 10.1177/15353702211054452. DOI: https://doi.org/10.1177/15353702211054452
Erman, H., Boyuk, B., Sertbas, M., & Ozdemir, A. (2022). Relationship between Metabolic Syndrome Components and COVID-19 Disease Severity in Hospitalized Patients: A Pilot Study. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale. DOI 10.1155/2022/9682032. DOI: https://doi.org/10.1155/2022/9682032
Holman, N., Knighton, P., Kar, P., O’Keefe, J., Curley, M., Weaver, A., … Valabhji, J. (2020). Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. The Lancet. Diabetes & Endocrinology, 8(10), 823-833. DOI 10.1016/S2213-8587(20)30271-0. DOI: https://doi.org/10.1016/S2213-8587(20)30271-0
Schmidt, M., & Duncan, B. (2003). Diabesity: An Inflammatory Metabolic Condition. Clinical Chemistry and Laboratory Medicine, 41(9), 1120-1130. DOI 10.1515/CCLM.2003.174. DOI: https://doi.org/10.1515/CCLM.2003.174
Chatterjee, P., Nagi, N., Agarwal, A., Das, B., Banerjee, S., Sarkar, S., … Gangakhedkar, R.R. (2020). The 2019 novel coronavirus disease (COVID-19) pandemic: a review of the current evidence. Indian J. Med. Res., 151, 147-159. DOI: https://doi.org/10.4103/ijmr.IJMR_519_20
Bertocchi, I., Foglietta, F., Collotta, D., Eva, C., Brancaleone, V., Thiemermann, C., & Collino, M. (2020). The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. British Journal of Pharmacology, 177(21), 4921-4930. DOI 10.1111/bph.15229. DOI: https://doi.org/10.1111/bph.15229
Halushko, O., Loskutov, O., Kuchynska, I., Synytsyn, M., & Boliuk, M. (2020). The main causes of the complicated course of COVID-19 in patients with diabetes mellitus and treatment (review). Georgian Medical News, 307, 114-120.
Colleluori, G., Graciotti, L., Pesaresi, M., Di Vincenzo, A., Perugini, J., Di Mercurio, E., … Cinti, S. (2022). Visceral fat inflammation and fat embolism are associated with lung’s lipidic hyaline membranes in subjects with COVID-19. International Journal of Obesity, 46(5), 1009-1017. DOI 10.1038/s41366-022-01071-w. DOI: https://doi.org/10.1038/s41366-022-01071-w
Wade, H., Duan, Q., & Su, Q. (2022). Interaction between Sars-CoV-2 structural proteins and host cellular receptors: From basic mechanisms to clinical perspectives. Advances in Protein Chemistry and Structural Biology, 132, 243-277. DOI 10.1016/bs.apcsb.2022.05.010. DOI: https://doi.org/10.1016/bs.apcsb.2022.05.010
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Bulletin of Social Hygiene and Health Protection Organization of Ukraine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.
2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.
3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).
